Companies related to Neurodegenerative diseases

We are a biotech company focused on developing precision medicines for neurological and immunological diseases.

We conduct world-class, collaborative, biological research and translate discoveries for the benefit of patients.

Advancing new technologies for brain health and neurostimulation

Creatively and diligently moving fast towards an effective treatment for people with ALS.

First-in-kind stem cell therapy to combat neurodegenerative diseases, giving back treatment perspective to millions

Our medical research will transform healthcare. We explore the full spectrum of disease to live life to the fullest.

Innovating Parkinson's Disease Care

Research-driven biotechnology company developing epigenetic therapies for the treatment of chronic disease

Innovating through embracing complexity

Fast-track your pipeline with preclinical excellence. in vitro & in vivo research services since 1991.

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s.

Developing transformative gene therapies for patients suffering from severe rare diseases.

BioArctic focuses on developing disease modifying treatments for neurodegenerative diseases.

Analytics and training, saving lives, improving performance & early-detecting cognitive impairment

Shifting the treatment paradigm for neurodegenerative disease towards precision medicine and disease prevention.

Developing innovative medicines for the treatment of neuropsychiatric and neurodegenerative diseases

Preclinical studies in gut and gut brain for therapies of tomorrow

Better Delivery for Better Care

Clinical-stage company developing novel therapeutics for diseases of high unmet need of the liver and nervous system

Neurotech & photomedicine

Right treatment. Right time. Real results.

Leader in Alzheimer's disease research. Discovery and development of treatment for dementia. Targeting tau.

Pinpointing Dementia Early

Therapeutic Solutions for Neurodegeneration

Leading the way in lysosomal ion channel biology to address neurodegenerative diseases and metabolic storage disorders